Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
   PubMed Web of Science ®Google Scholar
• Landstrom M, Damber JE, Bergh A. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Cancer Res 1994;54:4281-4
   PubMed Web of Science ®Google Scholar
• Klein LA, Engl N. Prostatic adenocarcinoma. J Med 1968;300:824-33
   Google Scholar
• Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical end-points for advanced prostate cancer. BJU Int 2005;96:985-9
   PubMed Web of Science ®Google Scholar
• Isaacs JT. The biology of hormone-refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-73
   PubMed Web of Science ®Google Scholar
• Schröder FH. Progress in understanding androgen-independent prostate cancer: a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53:1129-37
   PubMed Web of Science ®Google Scholar
• Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-9
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Feldman D. The development of androgen independent prostate cancer. Nat Rev Cancer 2001;1:34-45
   PubMed Web of Science ®Google Scholar
• Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett 2008;270:13-24
   Google Scholar
• Hadaschik B, Gleave M. Therapeutic options for hormone-refractory prostate cancer. Urol Oncol 2007;25(5):413-9
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94
   PubMed Web of Science ®Google Scholar
• Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(Suppl 3):1098-109
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cacner. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Fizazi K, Le Maitre A, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007;8(11):959-61
   PubMed Web of Science ®Google Scholar
• Williams G, Burin JR, Ball JA, et al. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Lancet 1986;2:774-7
   PubMed Web of Science ®Google Scholar
• Lamberts SWJ, Uitterlinden P, del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 1987;65:703-10
   PubMed Web of Science ®Google Scholar
• Ellison EC, O'Dorisio TM, Sparks J, et al. Observations on the effect of a somatostatin analog in the Zollinger-Ellison's syndrome: implications for the treatment of apudomas. Surgery 1986;100:437-44
   PubMed Web of Science ®Google Scholar
• Kvols LK, Moertel CG, O'Connel MJ, et al. Treatment of the malignant carcinoid symdrome. Evaluation of a long lasting somatostatin analogue. N Engl J Med 1986;315:663-6
   PubMed Web of Science ®Google Scholar
• Ahlman H, Ahlund L, Dahlstrom A, et al. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. Br J Cancer 1987;56:840-2
   PubMed Web of Science ®Google Scholar
• Hejna M, Schmidinger M, Raderer M. The clinical role of Somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13:653-68
   PubMed Web of Science ®Google Scholar
• Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17:1733-42
   PubMed Web of Science ®Google Scholar
• Newman JB, Lluis F, Townsend CM. Somatostatin. In: Thomson JC, Greeley GH Jr, Rayford PL, Townsend CM Jr, editors, Gastrointestinal Endocrinology. New York, NY: McGraw-Hill Book Co. 1987. p. 286-99
   Google Scholar
• Reichlin S. Secretion of somatostatin and its physiological function. J Lab Clin Med 1988;22:99-106
   Google Scholar
• Reichlin S. Somatostatin (first of two parts). N Engl J Med 1983;309:1495-501
   PubMed Web of Science ®Google Scholar
• Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983;309:1556-63
   PubMed Web of Science ®Google Scholar
• Longnecker SM. Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intell Clin Pharm 1988;22:99-106
   PubMedGoogle Scholar
• Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46
   PubMedGoogle Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98
   PubMed Web of Science ®Google Scholar
• Siegel RA, Tolcsvai L, Rudin M. Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). Cancer Res 1988;48:4651-5
   PubMed Web of Science ®Google Scholar
• Plonowski A, Schally AV, Nagy A, et al. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999;59:1947-53
   PubMed Web of Science ®Google Scholar
• Shimon I, Melmed S. Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 1997;155(Suppl 1):S3-6
   Google Scholar
• Freda P. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87(7):3013-8
   PubMed Web of Science ®Google Scholar
• Caron P, Morange-Ramos I, Cogne M, et al. Three-year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22
   PubMed Web of Science ®Google Scholar
• Suliman M, Jenkins R, Ross R, et al. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 1999;22(6):409-18
   PubMed Web of Science ®Google Scholar
• Cannavo S, Squadrito S, Curto L, et al. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 2000;32:224-9
   PubMed Web of Science ®Google Scholar
• Verhelst JA, Pedroncelli AM, Abs R, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000;143(5):577-84
   PubMed Web of Science ®Google Scholar
• Attanasio R, Barausse M, Cozzi R. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 2001;24(4):209-16
   PubMed Web of Science ®Google Scholar
• Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol 2004;60:734-40
   PubMed Web of Science ®Google Scholar
• Zambre Y, Ling Z, Chen MC, et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 1999;57:1159-64
   PubMed Web of Science ®Google Scholar
• Strowski MZ, Parmar RM, Blake AD, et al. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000;141:111-7
   PubMed Web of Science ®Google Scholar
• Drewe J, Sieber CC, Mottet C, et al. Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers. Clin Pharmacol Ther 1999;65:413-9
   PubMed Web of Science ®Google Scholar
• Lamrani A, Vidon N, Sogni P, et al. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997;43(1):65-70
   PubMed Web of Science ®Google Scholar
• Mottet C, Sieber CC, Nauer A, et al. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study. Hepatology 1998;27:920-5
   PubMed Web of Science ®Google Scholar
• Sobhani I, Rene E, Ramdani A. Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers. Br J Pharmacol 1996;41:109-14
   Web of Science ®Google Scholar
• Barbanoj M, Antonijoan R, Morte A, et al. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. J Clin Pharmacol 1999;66(5):485-91
   Google Scholar
• Tomlinson B, Thomas NG, Lan IW, et al. Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency. Clin Pharmacokinet 2006;45:1003-11
   PubMed Web of Science ®Google Scholar
• Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002;63:162-5
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99-104
   PubMed Web of Science ®Google Scholar
• Cendros JM, Peraire C, Fernandez-Troconiz I, et al. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism 2005;54:1276-81
   PubMed Web of Science ®Google Scholar
• Ciccarelli A, Daly A, Beckers A. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. Treat Endocrinol 2004;3(2):77-81
   PubMedGoogle Scholar
• Somatuline 60 mg, 90 mg, 120 mg. Electronic medicines Compendium. Available from: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=8203
   Google Scholar
• Antonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004;56:471-6
   PubMed Web of Science ®Google Scholar
• Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol 2000;85:4009-13
   Google Scholar
• Chanson P, Leselbaum A, Blumberg J, et al. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary 2000;2:269-76
   PubMedGoogle Scholar
• Giusti M, Gussoni G, Cuttica CM, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: 6-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab 1996:81:2089-97
   PubMed Web of Science ®Google Scholar
• Battaglia M, Ditonno P, Palazzo S, et al. Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancer. Scand J Urol Nephrol 2006;40(5):423-5
   PubMed Web of Science ®Google Scholar
• Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007;92:673-80
   PubMed Web of Science ®Google Scholar
• Galasco GSB. Mechanisms of lytic and blastic disease of the bone. Clin Orthopaed Rel Res 1982;12:20-7
   Google Scholar
• Koutsilieris M, Faure N, Laroche B, et al. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology 1986;27:221-7
   PubMed Web of Science ®Google Scholar
• Mertens WC, Stitt L, Porter AT. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol 1993;16(3):678-84
   Google Scholar
• Koutsilieris M. Skeletal metastasis in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 1995;18:51-64
   PubMed Web of Science ®Google Scholar
• Reyes-Moreno C, Sourla A, Choki I, et al. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology 1998;52:341-7
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs 2001;10:1099-115
   PubMed Web of Science ®Google Scholar
• Bogdanos J, Karamanolakis D, Tewnta R, et al. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 2003;10:279-89
   PubMed Web of Science ®Google Scholar
• Koutsilieris M, Frenette G, Lazure C, et al. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993;13:481-6
   PubMed Web of Science ®Google Scholar
• Boulanger J, Reyes-Moreno C, Koutsilieris M. Mediation of the glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG-63 osteoblast-like osteosarcoma cells. Int J Cancer 1995;61:692-7
   PubMed Web of Science ®Google Scholar
• Delany AM, Canalis E. Transcriptional regression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology 1995;136:4776-8
   PubMed Web of Science ®Google Scholar
• Reyes-Moreno C, Koutsilieris M. Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clin Exp Metastasis 1997;15:205-17
   PubMed Web of Science ®Google Scholar
• Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate 1999;38:313-6
   PubMed Web of Science ®Google Scholar
• Maulard C, Richaud P, Droz JP, et al. Phase I-II study of the somatostatin analog lanreotide inhormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995;36(3):259-62
   PubMed Web of Science ®Google Scholar
• Figg WD, Thibault A, Cooper MR, et al. A phase I study of the somatostatin analog somatulin in patients with metastatic hormone-refractory prostate cancer. Cancer 1995;75:2159-64
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Mosca A, et al. Effects of somatostatin analog lanreotide on the circulating levels of Chromogranin-A, Prostate Specific Antigen and Insulin-like Growth Factor-I in advanced prostate cancer. Prostate 2001;47:205-11
   PubMed Web of Science ®Google Scholar
• Koutsilieris M, Reyes-Moreno C, Sourla A, et al. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res 1997;17:1461-5
   PubMed Web of Science ®Google Scholar
• Koutsilieris M, Mitsiades C, Dimopoulos T, et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001;86:5729-36
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kiamouris C, Gika D, et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology 2004;63:120-5
   PubMed Web of Science ®Google Scholar
• Mitsogiannis IC, Oeconomou A, Gravas S, et al. The combination of lanreotide 90 mg plus dexamethasone in the treatment of hormone-refractory prostate cancer (HRPCA) [abstract 313]. Eur Urol Suppl 2007;6(2):101
   Google Scholar
• Robertson CN, Robertson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996;88:908-17
   PubMed Web of Science ®Google Scholar
• Sciarra A, Bosman C, Monti G, et al. Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 2004;172:1775-83
   PubMed Web of Science ®Google Scholar
• Sciarra A, Salciccia S. New treatment strategies in the management of hormone-refractory prostate cancer (HRPC): only chemotherapy? Eur Urol 2007;52:945-7
   PubMed Web of Science ®Google Scholar
• Di Silverio F, Sciarra A. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer. J Urol 2003;170:1812-6
   PubMed Web of Science ®Google Scholar